Status:
ENROLLING_BY_INVITATION
Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses th...
Eligibility Criteria
Inclusion
- For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes".
- Electronically provided consent obtained before any study-related activities can be completed.
- Age above or equal to 18 years at the time of providing informed consent.
- Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain.
- Have been prescribed and initiated injectable semaglutide for weight management prior to study screening.
- For an eligible participant (HCPs), all inclusion criteria must be answered "yes".
- Electronically provided consent obtained before any study-related activities can be completed.
- Practice in a participating country: Australia, Germany, UAE, and Spain.
- See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month.
- Treat at least 10 adult patients per month for weight management.
- Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs).
- Prescribe injectable semaglutide for weight management.
- Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others.
Exclusion
- For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no".
- Unwillingness or language barriers precluding adequate understanding or cooperation.
- Is currently or planning to become pregnant in next six months.
- Is taking injectable semaglutide for Type 2 diabetes management only.
- For an eligible participant (HCPs), all exclusion criteria must be answered "no".
- Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview.
- Unwillingness or language barriers precluding adequate understanding or cooperation.
- Only treats patients under 18 years of age.
Key Trial Info
Start Date :
September 26 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
2546 Patients enrolled
Trial Details
Trial ID
NCT07154238
Start Date
September 26 2025
End Date
September 30 2026
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Bad Oeynhausen, Germany, 32545